Verve Therapeutics Inc

NASDAQ:VERV  
34.34
+0.14 (+0.41%)
Products, Regulatory

Verve Therapeutics Reports Clearance Of Clinical Trial Authorisation Application By UK Health Regulator For Verve-101

Published: 09/21/2022 10:59 GMT
Verve Therapeutics Inc (VERV) - Verve Therapeutics Announces Clearance of Clinical Trial Authorisation Application by the United Kingdom Medicines and Healthcare Products Regulatory Agency for Verve-101 in Patients With Heterozygous Familial Hypercholesterolemia.
Verve Therapeutics Announces Clearance of Clinical Trial Authorisation Application by the United Kingdom Medicines and Healthcare Products Regulatory Agency for Verve-101 in Patients With Heterozygous Familial Hypercholesterolemia.